Discover 1,164 paid clinical trials in Cincinnati, Ohio. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
With a focus on a variety of conditions such as lymphoma, cancer, neurological diseases, and sleep apnea, Cincinnati is home to a wide array of clinical studies. The city's leading medical centers are actively recruiting participants, offering paid research opportunities for healthy volunteers or trials for specific health conditions, providing access to innovative treatments and therapies.
Filter
2
Filter results
Results: 1,164
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
for
Esophageal Cancer, Gastric Cancer (GC),
Location: Kettering OH, Indianapolis IN, Cleveland OH,
Sponsor: SOFIE
Sex: All
Age: 18+
Code: NCT07217704
Phase3, Recruiting
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)
for
Pancreatic Ductal Adenocarcinoma (PDAC)
Location: Kettering OH, Indianapolis IN, Cleveland OH,
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
for
Ovarian Cancer
Location: Centerville OH, Indianapolis IN, Ann Arbor MI,
Sponsor: Daiichi Sankyo
Sex: Female
Age: 18+
Code: NCT06819007
Phase3, Recruiting
Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
Location: Centerville OH, Columbus OH, Cleveland OH, Detroit MI,
Sponsor: HistoSonics, Inc.
Sex: All
Age: 22+
Code: NCT06486454
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)